ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

9:00AM-10:30AM: Abstract Number: 0661

Cutaneous Type I IFN Responses in Systemic Lupus Erythematosus Are Associated with Inflammatory Phenotype and Altered Wound Healing Function of Lupus Fibroblasts from Non-Lesional Skin

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0894

DAS28-gGT for the Prediction of Major Cardiovascular Events in Rheumatoid Arthritis: Results from the ESPOIR Cohort

RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0657

DB-2304, a Novel anti-BDCA2 Monoclonal Antibody Drug Conjugate, Displayed Great Potency in Suppression of pDC Functions

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0591

Deficiency of FUN14 Domain-Containing Protein 1-Mediated Mitophagy in Fibroblast-like Synoviocytes Causes Aggressive Behaviors Leading to Joint Destruction in Rheumatoid Arthritis

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0930

Delayed Response to Methotrexate Treatment in Rheumatoid Arthritis Patients Receiving Folic Acid Supplementation

RA – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 1021

Depression as a Modulator of Patient Reported, but Not Physician Observed, Outcomes in Psoriatic Arthritis

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 1000

Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis from the Phase 2 PAISLEY Study

SLE – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0724

Development of a Global Strategy to Strengthen Health Systems for Prevention and Management of Musculoskeletal Health

Health Services Research Poster II

9:00AM-10:30AM: Abstract Number: 0664

Development of a Novel Gene Expression-based Molecular Score That Characterizes Individual Lupus Patients

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0947

Development of a Person-Centered Family Planning Decision Aid for Women with Rheumatic Diseases

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-10:30AM: Abstract Number: 0971

Development of a Theory-based Educational Intervention for Fatigue in Systemic Lupus Erythematosus (SLE) Using Human-centered Design Methodology

Research Methodology Poster

9:00AM-10:30AM: Abstract Number: 0788

Development of Autoantibodies and Their Association with Flare-ups of Rheumatic Diseases in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) and the General Population Following BNT162b2 mRNA COVID-19 Vaccination – Results of 1-year Prospective Follow-up Study

Infection-related Rheumatic Disease Poster

9:00AM-10:30AM: Abstract Number: 0582

Development of Novel Glucocorticoid as Immunology Antibody-Drug Conjugate Payload for the Treatment of Autoimmune and Inflammatory Diseases

Cytokines and Cell Trafficking Poster

9:00AM-10:30AM: Abstract Number: 0852

Development, Refinement and Weighting of Candidate Criteria for Axial Disease in Juvenile Spondyloarthritis: An International Collaboration

Pediatric Rheumatology – Clinical Poster I: JIA

9:00AM-10:30AM: Abstract Number: 0902

Diagnosis of Mental Disorder Complicated by Rheumatoid Arthritis: A Study of the Validity of a Psychiatrist’s Diagnosis and Questionnaire Method

RA – Diagnosis, Manifestations, and Outcomes Poster II

«Previous Page
1
…
8
9
10
11
12
…
71
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].